Biosimilar User Fees Discounted To Begin Second Round
After adjusting for expected workload, US FDA reduces biosimilar user fee revenue target, which lowered application fees.

After adjusting for expected workload, US FDA reduces biosimilar user fee revenue target, which lowered application fees.